• Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial 

      Kasner S.E., Lavados P., Sharma M., Wang Y., Wang Y., Dávalos A., Shamalov N., Cunha L., Lindgren A., Mikulik R., Arauz A., Lang W., Czlonkowska A., Eckstein J., Gagliardi R., Amarenco P., Ameriso S.F., Tatlisumak T., Veltkamp R., Hankey G.J., Toni D.S., Bereczki D., Uchiyama S., Ntaios G., Yoon B.-W., Brouns R., DeVries Basson M.M., Endres M., Muir K., Bornstein N., Ozturk S., O'Donnell M., Mundl H., Pater C., Weitz J., Peacock W.F., Swaminathan B., Kirsch B., Berkowitz S.D., Peters G., Pare G., Themeles E., Shoamanesh A., Connolly S.J., Hart R.G., NAVIGATE ESUS Steering Committee and Investigators (2018)
      Background: The New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs. ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE-ESUS) trial is a randomized phase-III trial comparing ...